Cullinan Management (CGEM) Price & Analysis

Compare

281 Followers

CGEM Stock Chart & Stats

$7.31

-$0.28(-2.38%)

At close: Jan 08 4:00 PM EST

$7.31

-$0.28(-2.38%)

Day’s Range― - ―

52-Week Range$5.68 - $17.50

Previous CloseN/A

Volume73.34K

Average Volume (3M)1.28M

Market Cap

$437.15M

Enterprise Value$180.42M

Total Cash (Recent Filing)$265.48M

Total Debt (Recent Filing)$1.52M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Mar 05, 2026

EPS Estimate

-0.84

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.77

Shares Outstanding59,074,390

10 Day Avg. Volume896,300

30 Day Avg. Volume1,278,366

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)1.11

Price to Sales (P/S)0.00

P/FCF Ratio-4.51

Enterprise Value/Market Cap0.41

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-589.61

Enterprise Value/Ebitda-0.77

Forecast

1Y Price Target

$26.71

Price Target Upside265.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market Penetration OpportunityThere is potential for high market penetration for brain-penetrating drugs, which could significantly boost Cullinan's market presence.

Phase 1 CLN-049 DataCullinan's abstract at ASH reported promising Phase 1 data with CLN-049 in r/r AML, showing an encouraging initial clinical profile with minimal cytokine release syndrome.

Zipalertinib NDA FilingAn NDA filing is expected for accelerated approval, and the drug is currently in a Phase 3 trial for 1L patients, indicating a strong future potential for Cullinan.

Bears Say

Competition ChallengesDizal's Zegfrovy showed no CNS responses at the approved FDA dose, highlighting competition challenges faced by Cullinan.

FDA Approval RisksInability to receive FDA approval is a risk factor for the company, posing a significant threat to its future prospects.

TEAEs In TrialsThe most common TEAEs included CRS (40%) and infusion-related reaction (35%), indicating potential safety concerns in trials.

Cullinan Management News

Cullinan Therapeutics reports Q3 EPS (77c), consensus (89c)

“Cullinan is strategically focusing resources and development efforts on select, high-conviction clinical stage programs. We are well-positioned to...

16h ago

CGEM

Cullinan Therapeutics to showcase new data from Phase 1 study of CLN-049

Cullinan Therapeutics (CGEM) announced new clinical data from its Phase 1 study of CLN-049, a novel, investigational FLT3xCD3...

4d ago

CGEM

Cullinan Management: Strong Financials and Promising Pipeline Justify Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on CGEM stock, giving a Buy rating today....

4h ago

CGEM

Cullinan Management’s Promising Pipeline and Strategic Focus Earns Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on CGEM stock, giving a Buy rating on...

11h ago

CGEM

Cullinan Management Reports Strong Q3 2025 Financial Results

Cullinan Management ( ($CGEM) ) has shared an update. Cullinan Therapeutics announced its financial results for the third...

15h ago

CGEM

Promising Phase 1 Results for CLN-049 in AML Justify Buy Rating

Analyst Soumit Roy of JonesTrading maintained a Buy rating on Cullinan Management, retaining the price target of $34.00....

3d ago

CGEM

Cullinan Management Unveils Promising CLN-049 Clinical Data

Cullinan Management ( ($CGEM) ) has shared an announcement. On November 3, 2025, Cullinan Therapeutics announced promising new...

4d ago

CGEM

Promising Clinical Trial Results and Strategic Partnerships Drive Buy Rating for Cullinan Management

Morgan Stanley analyst Sean Laaman has maintained their bullish stance on CGEM stock, giving a Buy rating yesterday....

18d ago

CGEM

Buy Rating for Cullinan Management’s Zipalertinib: Promising Efficacy in Challenging EGFR Mutated NSCLC Cases

JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management today and set a price target of...

18d ago

CGEM

Promising Efficacy of Zipalertinib in EGFR NSCLC with CNS Involvement Justifies Buy Rating for Cullinan Management

Analyst Julian Harrison from BTIG maintained a Buy rating on Cullinan Management and keeping the price target at...

24d ago

CGEM

Promising Developments in Cullinan Management’s Zipalertinib Drive Buy Rating

Cullinan Management, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from...

25d ago

CGEM

Promising Trial Results and Strategic Plans Justify Buy Rating for Cullinan Management

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cullinan Management today and set a price target...

2M ago

CGEM

Cullinan Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $24 price target The company...

3M ago

CGEM

Cullinan has positive read from Novartis data, says Clear Street

After Novartis (NVS) announced that both of two Phase 3 trials evaluating ianalumab in adults with active Sjogren’s...

3M ago

NVS

CGEM

CGEM FAQ

What was Cullinan Management’s price range in the past 12 months?

Cullinan Management lowest stock price was $5.68 and its highest was $17.50 in the past 12 months.

What is Cullinan Management’s market cap?

Cullinan Management’s market cap is $437.15M.

When is Cullinan Management’s upcoming earnings report date?

Cullinan Management’s upcoming earnings report date is Mar 05, 2026 which is in 118 days.

How were Cullinan Management’s earnings last quarter?

Cullinan Management released its earnings results on Nov 06, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.947 by $0.177.

Is Cullinan Management overvalued?

According to Wall Street analysts Cullinan Management’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cullinan Management pay dividends?

Cullinan Management does not currently pay dividends.

What is Cullinan Management’s EPS estimate?

Cullinan Management’s EPS estimate is -0.84.

How many shares outstanding does Cullinan Management have?

Cullinan Management has 59,074,390 shares outstanding.

What happened to Cullinan Management’s price movement after its last earnings report?

Cullinan Management reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.947. Following the earnings report the stock price went down -10.787%.

Which hedge fund is a major shareholder of Cullinan Management?

Currently, no hedge funds are holding shares in CGEM

Cullinan Management Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.01%

Trailing 12-Months

Asset Growth

-23.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cullinan Management

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Management (CGEM) Earnings & Revenues

Historic Earnings Reports

CGEM Stock 12 Month Forecast

Average Price Target

$26.71

▲(265.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","35":"$35","12.5":"$12.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.5,20,27.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,10.60923076923077,12.55846153846154,14.507692307692308,16.456923076923076,18.40615384615385,20.355384615384615,22.304615384615385,24.253846153846155,26.203076923076924,28.152307692307694,30.101538461538464,32.050769230769234,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,10.048461538461538,11.436923076923076,12.825384615384616,14.213846153846154,15.602307692307692,16.99076923076923,18.37923076923077,19.767692307692307,21.156153846153845,22.544615384615383,23.933076923076925,25.321538461538463,{"y":26.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,9.686153846153847,10.712307692307693,11.73846153846154,12.764615384615386,13.790769230769232,14.816923076923077,15.843076923076923,16.869230769230768,17.895384615384614,18.92153846153846,19.947692307692307,20.973846153846154,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >